No Full Fed. Circ. Review In Genzyme Cancer Patent Case
Generic-drug maker Zydus Pharmaceuticals has lost its latest bid to get two patents covering Genzyme Corp.'s cancer medication Mozobil invalidated, with the Federal Circuit refusing to revisit its ruling clearing the...To view the full article, register now.
Already a subscriber? Click here to view full article